![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Saturday, February 16, 2008 7:12:58 PM
But the fast acting onset of intranasal delivery might be attractive to patients with these conditions, particularly when a strategic intervention might abort an otherwise serious pain event (ie eg coughing that exacerbates headache or sore throat pain, or prodromal migraine headache.)
What I know from my clinical practice is that pain meds that are approved and on the market are tried in a variety of off-label ways for a variety of pain conditions. Particularly notable are the chronic migraine patients who usually play the "pain management" game and settle on the med. or med. regimen that they've accepted as best for their personal response.
JM2C
aj
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM